Savara Inc
SVRA
NASDAQ
Biotechnology
$5.38
USD
+0.11 (+2.09%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $1.08B
Volume 1.7M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-139.31M
TTM
-26.3%
YoY
Operating Cash Flow
$-110.38M
TTM
-11.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 10.7 | 9.6 | 12.5 | 15.6 | 19.0 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 31.4 | 30.3 | 33.4 | 39.0 | 41.0 |
Operating Income | -31.4 | -30.3 | -33.4 | -39.0 | -41.0 |
EBITDA | -31.4 | -30.2 | -33.4 | -39.0 | -40.9 |
Other Income / Expense | 0.1 | 0.1 | -0.0 | -0.2 | -0.1 |
Total Other Income / Expense | 1.0 | 0.7 | 1.2 | 0.9 | 0.7 |
Income Before Income Taxes | -30.4 | -29.6 | -32.2 | -38.1 | -40.2 |
Income Taxes | 0.0 | 0.0 | 0.0 | -0.9 | 0.0 |
Net Income | -30.4 | -29.6 | -32.2 | -37.3 | -40.2 |
Consolidated Net Income / Loss | -30.4 | -29.6 | -32.2 | -37.3 | -40.2 |
Net Income Attributable to Common Shareholders | -30.4 | -29.6 | -32.2 | -37.3 | -40.2 |
Basic EPS | -$0.14 | -$0.14 | -$0.13 | -$0.15 | -$0.16 |
Diluted EPS | -$0.14 | -$0.14 | -$0.13 | -$0.15 | -$0.16 |
Basic Shares Outstanding | 216.4M | 216.5M | 240.5M | 253.3M | 253.6M |
Diluted Shares Outstanding | 216.4M | 216.5M | 240.5M | 253.3M | 253.6M |